Incyte Corporation (INCY) Shares are Up 3.82%

Incyte Corporation (INCY) : Traders are bullish on Incyte Corporation (INCY) as it has outperformed the S&P 500 by a wide margin of 10.17% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.27%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.82% in the last 1 week, and is up 7.94% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 1.82% and the 50-Day Moving Average is 1.63%.The 200 Day SMA reached 0.38% Incyte Corporation is up 6.54% in the last 3-month period. Year-to-Date the stock performance stands at -24.25%.


Incyte Corporation (INCY) : 11 investment research analysts covering Incyte Corporation (INCY) have an average price target of $100.55 for the near short term. The highest target price given by the Brokerage Firm to the stock is $135 and the lowest target is $90 for the short term. Analysts expect the variance to be within $12.47 of the average price.

For the current week, the company shares have a recommendation consensus of Buy. Incyte Corporation (NASDAQ:INCY): The stock opened at $80.35 and touched an intraday high of $82.57 on Friday. During the day, the stock corrected to an intraday low of $79.75, however, the bulls stepped in and pushed the price higher to close in the green at $82.15 with a gain of 2.23% for the day. The total traded volume for the day was 1,461,869. The stock had closed at $82.15 in the previous trading session.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.